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Summary
Background: Several lines of evidence indicate an in-
volvement of procolipase (CLPS) or its derivative enter-
ostatin in dietary fat absorption, regulation of fat intake, 
and body weight in rodents. We explored the relation-
ship between genetic variation in CLPS, early-onset 
obesity and fat intake in humans. Methods: We screened 
the CLPS in 93 extremely obese children and adoles-
cents and 96 underweight young adults for sequence 
variations and genotyped single nucleotide polymor-
phisms (SNPs) in extremely obese children and adoles-
cents, healthy normal- and underweight young adults 
and obesity trios. Case-control and family-based asso-
ciation analyses were performed. Results: Five sequence 
variations were identified: two non-synonymous SNPs: 
rs2766597 (Leu8Pro), rs41270082 (Arg109Cys); one SNP 
in the 5′UTR: rs3748050; one intronic SNP: rs3748051; 
and one infrequent novel non-synonymous variant: 
Arg55His. For rs2766597, rs3748050, and rs3748051 we 
obtained no evidence for an association with obesity in 
the case-control comparison. For rs41270082 there was a 
trend for association which could not be substantiated in 
the family-based association analysis. Additionally, we 
found no association in subgroup analyses pertaining 
to the extremely obese children and adolescents in the 
lowest and highest quartile of the percentage of energy 
consumed as fat. Conclusions: We found no evidence 
for an association of CLPS SNPs rs2766597, rs41270082, 
rs3748050, and rs3748051 with obesity or percentage of 
dietary fat intake.
Introduction
The colipase preproprotein (CLPS) is present in exocrine 
pancreatic cells and is secreted into the pancreatic juice [1]. 
CLPS expression is increased during feeding on fat and might 
provide a feedback signal for the inhibition of high levels 
of fat feeding [2]. After activation by trypsin, procolipase is 
split into the N-terminal pentapeptide enterostatin and the 90 
amino acid (aa) mature protein colipase [3]. The role of coli-
pase is to restore the activity of pancreatic lipase in the pres-
ence of inhibitory substances like bile acids [4]. Hence, it may 
be essential for the efficient digestion of dietary fat. 
Clps–/– mice show decreased postnatal survival and weight gain, 
steatorrhea on a high-fat diet, and reduced body weight com-
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pared to their Clps–/+ and wild-type littermates [5]. This indi-
cates that colipase, or its precursor procolipase, has additional 
functions in dietary fat digestion and body weight regulation in 
the period after birth when pancreatic lipase is not expressed. 
Studies involving the administration of enterostatin, either 
centrally or peripherally, demonstrated a dose-dependent and 
specific inhibition of fat intake in rats given a choice between 
fat, carbohydrate and protein [6], or an inhibition of high-fat 
intake as opposed to low-fat intake in a two-choice situation 
[7]. The inhibition of fat intake by enterostatin has been char-
acterized as an induction of early satiety [8]. Enterostatin acts 
through an interaction with a postulated μ-opioid pathway that 
affects reward perception and the production of ATP through 
an interaction with the β-subunit of F1F0 ATPase [9, 10]. In 
addition, there is evidence that enterostatin inhibits dietary 
fat intake through a melanocortin signaling pathway [11]. The 
effect of substances that stimulate fat intake, such as galanin 
[8], opioids [12–14] and glucocorticoid hormones [15], could be 
reduced by enterostatin treatment. In long-term studies enter-
ostatin was shown to decrease food intake and reduce body fat 
and body weight in rodents on a high-fat diet [16, 17]. Reduc-
tion of insulin and stimulation of corticosterone secretion [17, 
18], sympathetic stimulation of brown adipose tissue [19], and 
an increased thermogenesis [20] have been suggested to con-
tribute to these effects. In humans, it was suggested that enter-
ostatin secretion might be reduced in obesity, in both fasting 
and postingestive states [2, 21]. However, in clinical trials in-
travenous [22] and oral [23] administration of enterostatin did 
not reduce food intake in human subjects. 
The human procolipase gene (CLPS) is localized on chro-
mosome 6p21.31 and encodes a 112 aa preprotein. Given the 
presumed importance of CLPS for the regulation of fat intake 
and body weight regulation, we investigated if genetic vari-
ation in the CLPS is associated with early-onset obesity and 
fat intake in German samples comprising extremely obese 
children and adolescents and lean controls or nuclear families 
with extremely obese offspring.
Patients and Methods 
Study Subjects 
The ascertainment strategy was previously described in detail [24]. All 
extremely obese children and adolescents had an age- and gender-specific 
BMI percentile of 90 or higher as discussed previously [25] (98% had a 
percentile > 99). However, only parts of the total sample (table 1) were 
genotyped for each marker (table 2). The total case sample comprised 304 
extremely obese German children and adolescents who were recruited in 
hospitals specialized for the treatment of young in-patients with extreme 
obesity. 93 extremely obese children and adolescents, a subgroup of cases, 
were classified into 48 habitual high-fat (HF; 43–51% energy from fat) 
and 45 low-fat (LF; 21–36% energy from fat) consumers [27]. The per-
centage of energy consumed as fat was assessed using the ‘Leeds Food 
Frequency Questionnaire’ (Leeds FFQ) [26], which was adapted for Ger-
man nutritional habits. Consistency of the adapted FFQ was evaluated 
using a short FFQ validated in Germany [28]. The control sample com-
prised 325 healthy normal weight and underweight students; about 70% 
were lean (<15th percentile). They were recruited at the University of 
Marburg and reimbursed for their voluntary participation. The genotyped 
trio family sample included 365 extremely obese children and adolescents 
and both biological parents. All three samples were independent (table 
1). Written informed consent was given by all participants and, in the case 
of minors, their parents. This study was approved by the Ethics Commit-
tee of the University of Marburg and carried out in accordance with the 
Declaration of Helsinki.
Table 1. Anthropometric data of extremely obese children and adolescents (cases), underweight young adults (controls) and obese trio families (obese 
children and adolescents and both biological parents)a 
Study group Number Female/male BMI, kg/m2 Age, years Fat intakeb, %
Case sample of obese children and  304 163/141 33.47 ± 6.27 13.98 ± 2.35 ND 
  adolescents   (28.74;32.46;36.73) (12.53;14.02; 15.57)
Obese children and adolescents,   45  29/16 31.07 ± 1.99 13.57 ± 2.18 32.11 ± 4.15 
  LF consumer cases   (27.10;29.66;33.49) 12.41; 13.53 14.91) (30.00;33.00;35.00)
Obese children and adolescents,   48  20/28 32.15 ± 5.44 13.50 ± 1.98 45.46 ± 2.24 
  HF consumer cases   (27.30;30.69;35.90) 12.48; 13.28;15.00) (43.00;45.50;47.00)
Control sample of healthy underweight  325 157/168 19.36 ± 1.99 25.16 ± 3.48 ND 
  individuals   (17.72;18.95;20.79) (22.63;24.73;26.80)
Obese offspring  365 156/209 31.81 ± 6.04 13.75 ± 3.08 ND
  (children and adolescents)   (27.59;31.00;34.85) (12.14;13.84;15.58)
Parents 730 365/365 29.96 ± 6.22 42.68 ± 6.47 ND
   (25.59;29.10;33.17) (38.33;42.47;46.32)
a Values are given as absolute frequencies, mean ± SD and 1st, 2nd and 3rd quartile (in parentheses). Note that not all individuals were genotyped for 
all markers.
b As measured by the Leeds Food Frequency Questionnaire.
HF = High fat; LF = low fat; ND = not determined.




We designed three primer pairs to amplify the entire coding region and 
splice sites of CLPS. Primers were derived from the genomic sequence 
(GenBank accession number: NT_007592; www.ncbi.nlm.nih.gov) as fol-
lows: CLPS E1-F: 5′-GGT CAG GGC CCC TTT TAT AG-3′ and CLPS 
E1-R: 5′-TCA GAG GTC AAG GTC CAA GC-3′: 236 bp CLPS E1 
amplicon. CLPS E2-F: 5′-TGG GTA CAG GTC TGA ATG GA-3′ and 
CLPS E2-R: 5′-GTG TTC AGG GCC CTA CTC C-3′: 250 bp CLPS E2 
amplicon. CLPS E3-F: 5′-AGG GGA CAA GTG ATG TCC AA-3′ and 
CLPS E3-R: 5′-GCC TAC AGC ATT CTG GGC TA-3′: 239 bp CLPS 
E3 amplicon. Polymerase chain reaction (PCR) was performed according 
to standard protocols. For the mutation screen, single strand conforma-
tion polymorphism analysis (SSCP) was performed as described previous-
ly [29]. All amplicons with SSCP patterns deviant from the wild-type pat-
tern were sequenced as described previously [29]. To genotype Arg55His 
and rs41270082, a PCR with subsequent diagnostic restriction fragment 
length polymorphism analyses (RFLP) was performed. To genotype Ar-
g55His, CLPS E2 amplicon was digested by Fau I (NEB; G-allele: 150 bp 
and 100 bp, A-allele 250 bp). To genotype rs41270082, CLPS E3 amplicon 
was digested by Fok I (NEB; C-allele: 239 bp, T-allele 183 bp and 56 bp). 
To genotype rs3748050 and rs3748051 we performed a tetra-primer 
ARMS-PCR [30] with the following primers: 
– rs3748050 (50-i-F: 5′-CAC ACC AGC TGT CCC ACG CA-3′, 50-I-
R: 5′-CAG GAG GAT CAG GAT CTT CTC CAT TGC-3′, 50-o-F: 
5′-CCA CAG CAG ATT GGC CAC AGC T-3′ and 50-o-R: 5′-CCT 
GCC AGT CCA GGT GGA GAC A-3′). Sizes of the PCR prod-
ucts were 328 bp (outer primer pair), 204 bp (A-allele), and 171 bp 
(G-allele). 
– rs3748051 (51-i-F: 5′-AAG CGC CTC CTG AGT CCA CA-3′, 51-i-
R: 5′-GGT CCA AGC TTA GGA AGT CTT CAG CC-3′, 51-o-F: 
5′-ACC ACA GCT GGC TCT GTC TCC C-3′ and 51-o-R: 5′-CCA 
GGT TGA GCT GCT GCT CTG A-3′). Sizes of the PCR prod-
ucts were 371 bp (outer primer pair), 198 bp (A-allele) and 219 bp 
(G-allele). 
All PCR products were visualized on ethidium bromide-stained 2.5% 
agarose gels. Allele sizes were determined with a molecular weight stand-
ard (123 bp ladder, Gibco BRL, Karlsruhe, Germany). Trio analyses for 
rs41270082 were performed by high-throughput genotyping via matrix-
assisted laser desorption/ionization, time-of-flight mass spectrometry 
(MALDI-TOF-MS), employing the homogeneous mass extension proto-
col provided by the manufacturer (Sequenom, San Diego, CA, US). As-
says for the SNP were designed by the SpectroDesigner software (Seque-
nom). Note that different numbers of individuals were genotyped for each 
marker such that the numbers in table 1 and table 2 do not correspond, 
i.e. table 1 indicates the maximum number of individuals that could have 
been genotyped.
Statistical Analysis 
Differences in genotype frequencies for a dominant genetic model be-
tween samples of unrelated subjects were investigated using Fisher’s 
exact test. This genetic model was chosen because most SNPs had rather 
low minor allele frequencies, leading to a low number of observations 
per cell in the 2×3 frequency table. The exact version, i.e. the binomial 
test of the classical test [31] for transmission disequilibrium, was used 
for the trio analysis. All genotype distributions in controls and parents 
were tested for deviations from Hardy-Weinberg equilibrium (HWE) 
Table 2. Genotype distributions and association analyses for four CLPS SNPs on chromosome 6 in obese children and adolescents (cases) compared 
with underweight and normal weight young adults (controls). In addition a subgroup of the obese children and adolescents was derived from the quar-
tiles of percentage of energy consumed fat (LF vs. HF consumers) and compared with each other or with the controlsa 
 Marker  Physical  Cases  Controls OR estimate LF consumer HF consumer OR estimate
genotypes position (bp)     p value cases  cases  p value
 dbSNP127     
  --------- ---------  ---------- ---------- --------------------------------
   n % n % Cases vs.  %  n % n LF vs. HF LF vs.   HF vs. 
      controls      controls controls
rs2766597 35873021
 CC    0  0.0   0  0.0 0.35  0   0.0  0  0.0 ND ND 0.70
 TC    2  2.1  19  5.9 (0.04; 1.48)   0   0.0  2  4.2   (0.08; 3.07)
 TT   93 97.9 306 94.1 0.22 45 100.0 46 95.8 0.53 0.16 0.95
rs3748050 35873046
 GG    1  1.2   8  3.9 0.82  1   2.2  0  0.0 0.67 0.71 1.07
 AG   35 42.2  91 44.4 (0.47; 1.41) 17  37.8 24 50.0 (0.27; 1.64) (0.37; 1.38) (0.54; 2.11)
 AA   47 56.6 106 51.7 0.53 27  60.0 24 50.0 0.45 0.40 0.96
rs3748051 35872921
 GG    1  1.2   8  3.9 0.83  1   2.6  0  0.0 0.65 0.64 0.98
 AG   36 43.4  93 45.4 (0.48; 1.43) 14  35.9 21 48.8 (0.25; 1.72) (0.29; 1.37) (0.48; 2.00)
 AA   46 55.4 104 50.7 0.55 24  61.5 22 51.2 0.47 0.29 1.00
rs41270082 35870915
 TT    0  0.0   0  0.0 3.45  0   0.0  0  0.0 1.07 5.38 5.02
 CT   12  4.4   3  1.3 (0.91; 19.25)  3   6.7  3  6.3 (0.14; 8.44) (0.69; 41.18) (0.65; 38.4)
 CC  262 95.6 226 98.7 0.07 42  93.3 45 93.7 1.00 0.12 0.13
ND = Not determined.
aOdds ratios (OR) estimates with 95% confidence intervals in parenthesis and p values were calculated under a dominant genetic model with the 
minor allele as risk allele.
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using PEDSTATS 0.6.4 [32], and no evidence for such deviations were 
detected (all p ≥ 0.01). As there was no evidence for a significant asso-
ciation, no correction for multiple testing was performed. All reported p 
values were nominal, two-sided, and exact. In addition, estimated odds 
ratios and 95% confidence intervals are provided under the dominant 
genetic model. For that same genetic model the power of the analysis 
was assessed with the software QUANTO Version 1.2.3 (http://hydra.
usc.edu/gxe) for rs3748050 (HapMap-CEU minor allele frequency ≈ 
29%). Based on this information 200 case-control pairs were estimated 
to yield a power >80% to detect a genetic odds ratio of 1.8 (α = 0.05; 
two-sided). For the 365 trio families the power estimate was >80% to 
detect a genotype relative risk of 1.5 (α = 0.05; two-sided). Thus, the 
association studies were only well powered to detect common disease-
predisposing variants with strong genetic effects.
Results
The initial mutation screen of the coding sequence of CLPS 
in 93 extremely obese children and adolescents (a subgroup 
of the case sample) and 96 healthy lean young adults (a sub-
group of the control sample) revealed two previously de-
scribed missense SNPs (rs2766597 (Leu8Pro) and rs41270082 
(Arg109Cys)) and two non-coding SNPs (rs3748050 in 
the 5′UTR and rs3748051 in intron 1). In addition, a novel 
non-synonymous, non-conservative variant (g.1515G>A: 
Arg55His) was found in one control proband in the hetero-
zygous state. Due to its very low estimated minor allele fre-
quency (MAF = 0.27% in our sample) and the low statistical 
power resulting, this variant was not evaluated further in the 
case-control association analyses. rs41270082 resulted in an 
Arg to Cys substitution at position 109 of CLPS. The case-
control analysis revealed some evidence for a difference in 
T-allele frequencies between cases and controls (p = 0.07). 
In an attempt to substantiate this finding, we genotyped 
rs41270082 in the 365 obesity trio families. Only 3 transmis-
sions versus 7 non-transmissions of the T-allele to the obese 
offspring could be detected by the transmission disequilib-
rium test (TDT) (p = 0.34). Hence, the initial result was not 
substantiated; descriptively the potential ‘risk allele’ was 
transmitted less frequently to the obese offspring. rs2766597 
predicted a non-conservative aa exchange replacing Leu at 
position 8 of CLPS with Pro (Leu8Pro). Association analyses 
for rs2766597 and the other two detected SNPs (rs3748050 
and rs3748051) revealed no differences in genotype distri-
butions between extremely obese cases and controls (all 
p ≥ 0.2). 
Finally, we explored in 93 extremely obese individuals wheth-
er any of the genotyped SNPs might be more strongly asso-
ciated with the dichotomized endophenotype ‘percent of en-
ergy consumed as fat’. None of these additional comparisons 
revealed any evidence for differences in genotype frequencies 
between extremely obese patients of the low and high quartile 
of the percentage of energy consumed as fat (all p ≥ 0.4) or for 
the comparisons to the lean controls (all p ≥ 0.1).
Discussion
To determine the influence of genetic variants within CLPS on 
early-onset obesity in humans, we systematically screened the 
coding sequence of CLPS for sequence variations in a total of 
189 German, extremely obese, normal or lean individuals. This 
sample size is sufficient to allow for the detection of common 
variants (e.g. assuming a minor allele frequency of 0.05, the 
total sample size produced a 95% confidence interval ± 0.03). 
Two previously described non-synonymous SNPs (rs2766597 
and rs41270082) and two non-coding SNPs (rs3748050 in the 
5′UTR and rs3748051 in intron 1) were identified along with 
one novel infrequent missense variant (Arg55His). In our as-
sociation studies, we initially compared genotype frequencies 
of these four SNPs in CLPS between extremely obese chil-
dren and adolescents and lean controls. While no evidence for 
an association for rs3748050, rs2766597, and rs3748051 was 
obtained, there was some evidence for an association between 
the T-allele of rs41270082 and obesity. This SNP, in codon 109 
of CLPS, results in an Arg to Cys substitution. Since CLPS 
contains 10 Cys residues, which form 5 disulfide bridges, an 
additional Cys residue at position 109 may alter the bridge 
formation and therefore the stability, conformation and/or 
function of the protein. Because of these potential functional 
consequences, we performed subsequent TDTs in 365 obes-
ity trios. Tests revealed no evidence for transmission disequi-
librium and therefore did not substantiate the initial finding. 
However, it is possible that this result might only be due to 
the insufficient power of the family-based approach. Finally, 
we also assessed whether one of the four variants might be 
associated with differences in dietary fat consumption of ex-
tremely obese individuals defined by upper and lower quar-
tiles within the case sample. As with the main finding, we 
found no evidence for differences in genotype frequencies be-
tween habitual high-fat and low-fat consumers. The same was 
true for the comparisons with the control group.
Association of rs3748050 and rs3748051 with reduced insulin 
secretion in non-diabetic Caucasians was recently detected 
[33]. Furthermore, previous work suggested a contribution 
of rs41270082 in CLPS to increased susceptibility to type 2 
diabetes mellitus in two German study populations [34]. Very 
recently, evidence for an association with type 2 diabetes was 
detected in the EPIC-Potsdam cohort by screening for se-
quence variants in 15 genes involved in fat assimilation [35]. 
In an in vitro study rs41270082 was found to decrease the 
function of colipase [36]. So far, in public association databas-
es associations of CLPS variants with obesity traits have not 
been reported. Studies of the potential implication of CLPS 
sequence variants in obesity would benefit from further analy-
ses of rs41270082 in larger samples of obese subjects.
In conclusion, this investigation did not detect any common 
variants in the coding region and 5′UTR of CLPS with a 
major impact for the development of early onset obesity or 
habitual fat intake. However, larger samples will be neces-
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sary to assess moderate genetic effects and their relationship 
to obesity. Even though limited by the small sample size, the 
present study may thus contribute to meta-analytic approach-
es addressing the role of the investigated polymorphisms for 
the development of early-onset extreme obesity.
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